Slide 1: Corporate Presentation March 2022
CORPORATE PRESENTATION March 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical fa
Slide 3: What We Do
WHAT WE DO Developing innovative oral biotherapeutics for gastrointestinal health and beyond. TARGETED THERAPEUTICS SYSTEMIC THERAPEUTICS PGN-001 Adalimumab variant + DDS PGN-OB1 Adalimumab variant + OBDS PGN-OB2 GLP-1 agonist + OBDS Ionis Pharma Antisense therapy + OBDS Large Pharma 1 Undisclosed d
Slide 4: Therapeutics Pipeline
PROGRAM PROGRAM INDICATION DESIGN/FEASIBILITY PRECLINICAL CLINICAL TARGETED THERAPEUTICS DDS IBD PGN-600 Ulcerative Colitis PGN-001 Ulcerative Colitis SYSTEMIC THERAPEUTICS OBDS -- PGN-OB1 Autoimmune PGN-OB2 Diabetes -- Undisclosed -- Undisclosed -- Undisclosed THERAPEUTICS PIPELINE GLP-1 agonist +
Slide 5: Targeted Therapeutics
TARGETED THERAPEUTICS
Slide 6: Ulcerative Colitis: The Treatment Gap
Despite advanced therapeutics targeting different pathways, few patients achieve long-term remission ULCERATIVE COLITIS: THE TREATMENT GAP Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6(7)
Slide 7: Targeted Therapeutics: A Potential Solution for Unmet Need in UC
TARGETED THERAPEUTICS: A POTENTIAL SOLUTION FOR UNMET NEED IN UC Verstockt B, Alsoud D, van Oostrom J, et al. Tofacitinib tissue exposure correlates with endoscopic outcome. Oral presentation at the 34th edition of the Belgian Week of Gastroenterology, February 9, 2022. Alsoud D, Verstockt B, Fiocch
Slide 8: Our IBD Solution: Targeted Therapeutics
OUR IBD SOLUTION: TARGETED THERAPEUTICS Targeted drug delivery to the GI tract designed to improve efficacy and safety Targeted delivery designed to improve endoscopic outcomes by increasing drug levels at the site of disease Payload delivery method designed to minimize systemic uptake, potentially
Slide 9: Targeted Therapeutics: Preclinical Results
TARGETED THERAPEUTICS: PRECLINICAL RESULTS BETTER PK EFFECT & COVERAGE Pharmacokinetic data from two marker drugs administered in canine model indicated: Successful delivery to colon via DDS No early release of drug No drug absorption in upper GI tract Standard oral dose vs. PGN-600 (tofacitinib del
Slide 10: Targeted Therapeutics: Clinical Device Performance
TARGETED THERAPEUTICS: CLINICAL DEVICE PERFORMANCE Accurate localization and delivery demonstrated in humans Successful clinical device validation for localization and delivery function using scintigraphic imaging: Safety and tolerability in normal healthy volunteers; devices recovered intact 83% ac
Slide 11: Targeted Delivery: Superior Pharmacodynamics in Multiple Molecules
TARGETED DELIVERY: SUPERIOR PHARMACODYNAMICS IN MULTIPLE MOLECULES Anti-TNFα in animal models Systemic delivery via intraperitoneal injection (IP) vs. targeted intracecal delivery (IC) of anti-TNFα in mouse model of T-cell transfer colitis demonstrated: Significantly improved histopathology score vs
Slide 12: Targeted Therapeutics Clinical Plan
TARGETED THERAPEUTICS CLINICAL PLAN FUNCTION STUDIES TOX STUDY PHASE 1 CLINICAL STUDIES PHASE 1B/2A CLINICAL STUDIES PM-601 Device Function Study in Normal Healthy Volunteers Device was well tolerated Achieved pan-colon distribution of payload Accurately identified entry into the colon (10/12); no e
Slide 13: Systemic Therapeutics
Rx SYSTEMIC THERAPEUTICS
Slide 14: Needle Aversion Leads to Poor Patient Adherence
among diabetes patients initiating treatment with injectable GLP-1 agonist NEEDLE AVERSION LEADS TO POOR PATIENT ADHERENCE Patients prefer oral delivery of medication Wright S, Yelland M, Heathcote K, Ng SK, Wright G. Fear of needles--nature and prevalence in general practice. Aust Fam Physician. 20
Slide 15: Systemic Therapeutics Delivery System
SYSTEMIC THERAPEUTICS DELIVERY SYSTEM Needle-free, oral delivery to small intestine designed for optimal systemic uptake Needle-free, liquid jet administration to intestinal tissue for enhanced systemic uptake More frequent administration vs. injection may improve outcomes Versatile platform can del
Slide 16: Systemic Therapeutics: Precision Delivery
SYSTEMIC THERAPEUTICS: PRECISION DELIVERY Preclinical studies demonstrate precise and reliable release of payload ACCURATE DELIVERY IN SMALL INTESTINE STUDY DESIGN RESULTS Capsule loaded with a radio-opaque marker (iohexal) Two different enteric triggers evaluated Sequential imaging as the capsule t
Slide 17: Excellent Systemic Uptake for Orally Delivered Large Molecules
EXCELLENT SYSTEMIC UPTAKE FOR ORALLY DELIVERED LARGE MOLECULES Demonstrated up to 67% bioavailability for monoclonal antibodies Progenity internal data Multiple studies in swine model with endoscopically placed, autonomous device compared to IV administration Achieved up to 67% bioavailability for a
Slide 18: Milestones & Corporate Highlights
MILESTONES & CORPORATE HIGHLIGHTS
Slide 19: Other Platforms in Development
OTHER PLATFORMS IN DEVELOPMENT PLATFORM DESCRIPTION DEVELOPMENT PLANS RSS: RECOVERABLE SAMPLING SYSTEM Ingestible capsule designed to autonomously identify locations in the GI tract, collect and preserve a sample for recovery and analysis. Presenting microbiome sampling data at DDW 2022 Continuing d
Slide 20: Near-Term Potential Catalysts
PROGRAM Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 ENABLES PM-611 PM-602 Establishes device performance in healthy volunteers & UC patients PRECLINICAL TOXICOLOGY Preclinical toxicology to support phase 1b/2a study PHASE 1 CLINICAL TRIAL Evaluate the safety & tolerability, PK/PD of PGN-600 subject to F
Slide 21: Progenity
progenity’